Literature DB >> 8163694

Prevalence of Chlamydia pneumoniae antibodies in patients with acute respiratory infections in Israel.

M Ben-Yaakov1, Z Lazarovich, S Beer, A Levin, I Shoham, I Boldur.   

Abstract

AIMS: To evaluate the prevalence of antibodies to Chlamydia pneumoniae (TWAR) in relation to other aetiological agents of acute respiratory infections in Israeli patients.
METHOD: Serum samples from 604 patients (183 children and 421 adults) were collected over three years. Antibodies to C pneumoniae, C trachomatis, and Legionella sp were evaluated using the microimmunofluorescence (MIF) assay. Antibodies to Mycoplasma pneumoniae were detected using the Serodia Myco II test.
RESULTS: Antibodies to TWAR were detected in 319 (51.3%) sera. Twenty one patients had MIF results indicative of recent infection. TWAR prevalence and antibody titres in children (aged 1-10 years) were low, gradually increased in teenagers (11-18 years), and were highest in adults and elderly patients. In contrast to the consistently noted TWAR antibody prevalence and serological evidence of recent infection during the study period, a significant decrease in those variables was recorded for C trachomatis. Six patients had serological evidence of recent infection with both C pneumoniae and C trachomatis. The presence of antibodies to Mycoplasma pneumoniae and Legionella sp was tested in 473 of the patients; 29 had antibodies to M pneumoniae and 23 to Legionella sp. Six patients (including five children) had serological evidence of recent infection with M pneumoniae and four with Legionella sp.
CONCLUSION: C pneumoniae should be considered in patients with acute respiratory diseases. MIF is the preferred method for monitoring the presence of antibodies to this organism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163694      PMCID: PMC501901          DOI: 10.1136/jcp.47.3.232

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  27 in total

1.  Evaluation of Serodia Myco II particle agglutination test for detecting Mycoplasma pneumoniae antibody: comparison with mu-capture ELISA and indirect immunofluorescence.

Authors:  C E Barker; M Sillis; T G Wreghitt
Journal:  J Clin Pathol       Date:  1990-02       Impact factor: 3.411

2.  Prevalence of antibodies to Chlamydia pneumoniae in a pediatric hospital population in Belgium.

Authors:  L Van Renterghem; A M Van den Abeele; G Claeys; J Plum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

3.  Age-related interference with Chlamydia pneumoniae microimmunofluorescence serology due to circulating rheumatoid factor.

Authors:  R P Verkooyen; M A Hazenberg; G H Van Haaren; J M Van Den Bosch; R J Snijder; H P Van Helden; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

4.  Measure of immunoglobulin G-, M-, and A-specific titers against Legionella pneumophila and inhibition of titers against nonspecific, gram-negative bacterial antigens in the indirect immunofluorescence test for legionellosis.

Authors:  H W Wilkinson; C E Farshy; B J Fikes; D D Cruce; L P Yealy
Journal:  J Clin Microbiol       Date:  1979-11       Impact factor: 5.948

5.  Infection with Chlamydia pneumoniae in Brooklyn.

Authors:  K Chirgwin; P M Roblin; M Gelling; M R Hammerschlag; J Schachter
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

6.  Legionnaires's disease.

Authors:  J Berman; G Loon; E Rubinstein
Journal:  Isr J Med Sci       Date:  1979-03

7.  Chlamydia pneumoniae infections in Norway 1981-87 earlier diagnosed as ornithosis.

Authors:  A L Bruu; G Haukenes; S Aasen; J T Grayston; S P Wang; O G Klausen; H Myrmel; V Hasseltvedt
Journal:  Scand J Infect Dis       Date:  1991

8.  Specificity of the microimmunofluorescence assay for the serodiagnosis of Chlamydia pneumoniae infections.

Authors:  G Ozanne; J Lefebvre
Journal:  Can J Microbiol       Date:  1992-11       Impact factor: 2.419

9.  Application of an indirect immunofluorescence test for detection of Mycoplasma pneumoniae in respiratory exudates.

Authors:  Y Hirai; J Shiode; T Masayoshi; Y Kanemasa
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

10.  Prevalence of antibody to Chlamydia pneumoniae TWAR in japan.

Authors:  Y Kanamoto; K Ouchi; M Mizui; M Ushio; T Usui
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

View more
  5 in total

Review 1.  Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis.

Authors:  S J Bourke; N F Lightfoot
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

2.  Prevalence of antibodies to Chlamydia pneumoniae in an Israeli population without clinical evidence of respiratory infection.

Authors:  M Ben-Yaakov; G Eshel; L Zaksonski; Z Lazarovich; I Boldur
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

3.  Prevalence of specific antibodies to Chlamydia pneumoniae in Korea.

Authors:  T Y Choi; D A Kim; S K Kim; J O Kang; S S Park; S R Jung
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

4.  Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections.

Authors:  R P Verkooyen; D Willemse; S C Hiep-van Casteren; S A Joulandan; R J Snijder; J M van den Bosch; H P van Helden; M F Peeters; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

5.  Multi-peptide ELISAs overcome cross-reactivity and inadequate sensitivity of conventional Chlamydia pneumoniae serology.

Authors:  Kh Shamsur Rahman; Bernhard Kaltenboeck
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.